How can artificial intelligence and machine learning be applied to B cell research?

Dec 1, 2018 ... The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas. Dec 15, 2020 ... BCDTs such as those targeting CD20, CD19 and BAFF are now used to treat autoimmune diseases, including systemic lupus erythematosus and multiple sclerosis. B-cell lymphoproliferative disorders are conditions in the blood involving uncontrolled growth of white blood cells, also called lymphocytes. These conditions ... Aug 19, 2024 ... This trial represents the largest randomized study of radiotherapy in PMBCL to date. Despite encountering challenges due to unexpectedly good ... Jan 4, 2024 ... 10:07 Go to channel Understanding Diffuse Large B-Cell Lymphoma with Bruce Cheson, MD, FACP, FAAAS, FASCO Lymphoma Research Foundation ... cells, B cells, and plasma cells secreting pathogenic autoantibodies will be illuminated. The importance of cognate B cell help to autoreactive T cells will ... B cell markers · Plasma B cells: a plasma cell is the sentry of the immune system. · Memory B cells: · B-1 cells: · Marginal zone (MZ) B cells: · Follicular (FO) ... Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is ... Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent ... The finding gives oncologists a new target for developing immunotherapies: double negative memory B cells, so-called because they are negative for two markers.